Fulgent Genetics, Inc.
FLGT- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- SEC CIK
- 0001674930
In the last 90 days, Fulgent Genetics, Inc. insiders filed 0 open-market purchases and 4 sales; 141 institutions reported holding it in 13F filings for Q2 2026, worth $321.8M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $720.3M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $117.1K in total
- 4
- 13F holdersQ2 2026, −16 vs. previous quarter
- 141
- 13F valueReported value at the end of Q2 2026
- $321.8M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $322.7M
- +13.8% year over year
- Net income, FY2025
- -$60.5M
- No comparable prior period
- Free cash flow, FY2025
- -$124.2M
- No comparable prior period
- Revenue, Q3 FY2026
- $90.4M
- +7.5% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $60.5M (18.8% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 2.02M
- Shares sold short
- Change
- −115.1K
- −5.4% vs. previous
- Days to cover
- 7.81
- At average daily volume
Superinvestors holding FLGT, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding FLGT at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Fulgent Genetics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 (view filing)7:47 PM ET | Sep 2 | 1 day | Gao HanlinChief Scientific Officer | SSale | −1.67K | $19.66 | −$32.9K | −0.2%986.1K after | |
| Sep 3, 2026 (view filing)7:47 PM ET | Sep 2 | 1 day | Xie JianPresident and COO | SSale | −2.13K | $19.66 | −$41.8K | −0.6%359.9K after | |
| Aug 28, 2026 (view filing)6:06 PM ET | Aug 27 | 1 day | Xie JianPresident and COO | SSale | −1.19K | $19.91 | −$23.7K | −0.3%362.1K after | |
| Aug 28, 2026 (view filing)6:05 PM ET | Aug 27 | 1 day | Gao HanlinChief Scientific Officer | SSale | −939 | $19.91 | −$18.7K | −0.1%987.8K after | |
| Jun 3, 2026 (view filing) | Jun 2 | 1 day | Xie JianPresident and COO | SSale | −2.15K | $17.89 | −$38.4K | −0.6%367.6K after | |
| Jun 3, 2026 (view filing) | Jun 2 | 1 day | Gao HanlinChief Scientific Officer | SSale | −1.69K | $17.89 | −$30.2K | −0.2%990.4K after | |
| May 28, 2026 (view filing) | May 27 | 1 day | Xie JianPresident and COO | SSale | −1.20K | $17.60 | −$21.1K | −0.3%369.8K after | |
| May 28, 2026 (view filing) | May 27 | 1 day | Gao HanlinChief Scientific Officer | SSale | −945 | $17.60 | −$16.6K | −0.1%992.1K after | |
| Dec 3, 2025 (view filing) | Dec 2 | 1 day | Xie JianPresident and COO | SSale | −1.14K | $28.33 | −$32.3K | −0.3%336.7K after | |
| Dec 3, 2025 (view filing) | Dec 2 | 1 day | Gao HanlinChief Scientific Officer | SSale | −1.07K | $28.33 | −$30.5K | −0.1%952.9K after |
Top 10 13F holders, Q2 2026
See all 141 holdersThe largest institutional positions in Fulgent Genetics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 2,286,669 | $46.9M | 0.00% | −487,850−17.6% | Reduced |
| Acadian Asset Management LLC | 1,017,913 | $20.9M | 0.02% | −216,038−17.5% | Reduced |
| Vanguard Capital Management LLC | 789,498 | $16.2M | 0.00% | −90,652−10.3% | Reduced |
| Jacobs Levy Equity Management, Inc | 782,116 | $16.0M | 0.06% | +425,757+119.5% | Added |
| JPMorgan Chase & Co | 756,558 | $15.5M | 0.00% | +296,195+64.3% | Added |
| Diametric Capital, LP | 697,784 | $14.3M | 1.52% | +336,738+93.3% | Added |
| Ameriprise Financial Inc | 670,084 | $13.8M | 0.00% | +106,709+18.9% | Added |
| Dimensional Fund Advisors LP | 625,355 | $12.8M | 0.00% | −46,309−6.9% | Reduced |
| Geode Capital Management, LLC | 521,014 | $10.7M | 0.00% | −63,193−10.8% | Reduced |
| State Street Corp | 498,673 | $10.2M | 0.00% | −30,726−5.8% | Reduced |
Holders of 5% or more of FLGT
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Fulgent Genetics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Hsieh Ming | 13D/A | 32.26%8.87M shares | +1.52 ppfrom 30.74% | Nov 10, 20224 filings | May 27, 2026 | SEC |
| Barclays PLC | 13G/A | 7.57%2.34M shares | +2.15 ppfrom 5.42% | Feb 7, 20253 filings | May 13, 2025 | SEC |
| BlackRock, Inc. | 13G/A | 5.90%1.82M shares | – | Apr 3, 20251 filing | Apr 3, 2025 | SEC |